| Page 1173 | Kisaco Research
 

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)
 

Joël Plumas

Co-founder & CSO
PDC*Line Pharma

Joël Plumas

Co-founder & CSO
PDC*Line Pharma

Joël Plumas

Co-founder & CSO
PDC*Line Pharma
 

Joachim Koch

VP, Translational Immunobiology
Affimed

Joachim Koch

VP, Translational Immunobiology
Affimed

Joachim Koch

VP, Translational Immunobiology
Affimed
 

Inna Menkova

Co-founder & CEO
Allogenica

Inna Menkova

Co-founder & CEO
Allogenica

Inna Menkova

Co-founder & CEO
Allogenica
 

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy
 

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult
 

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier
 

Gil Beyen

CEO
ERYTECH Pharma

Gil Beyen

CEO
ERYTECH Pharma

Gil Beyen

CEO
ERYTECH Pharma
 

Filipe Pereira

Associate Professor at Lund University and Co-founder & Head of Innovation
Asgard Therapeutics

Filipe Pereira

Associate Professor at Lund University and Co-founder & Head of Innovation
Asgard Therapeutics

Filipe Pereira

Associate Professor at Lund University and Co-founder & Head of Innovation
Asgard Therapeutics
 

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis